Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis

Journal of Clinical Endocrinology and Metabolism

Volumn 88, Issue 2, 2003, Pages 569-575

  Horwitz, Mara J ^a   Tedesco, Mary Beth ^a   Gundberg, Caren ^b   Garcia Ocana, Adolfo ^a   Stewart, Andrew F ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; CALCIUM; COLLAGEN TYPE 1; DEOXYPYRIDINOLINE; OSTEOCALCIN; PARATHYROID HORMONE RELATED PROTEIN; PEPTIDE; UNCLASSIFIED DRUG; VITAMIN D;

ADULT; ARTICLE; BONE DENSITY; BONE MINERAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; FEMALE; HORMONE SUBSTITUTION; HUMAN; LUMBAR SPINE; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

BIOLOGICAL MARKERS; BONE DENSITY; CALCIUM; DOUBLE-BLIND METHOD; FEMALE; FEMUR NECK; HIP JOINT; HUMANS; LUMBAR VERTEBRAE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PARATHYROID HORMONE; PARATHYROID HORMONE-RELATED PROTEIN; PATIENT COMPLIANCE; PEPTIDE HORMONES; PILOT PROJECTS; PROSPECTIVE STUDIES;

EID: 0037323386     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2002-021122     Document Type: Article

References (41)

1. The writing group for the PEPI trial 1996 The effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA 276:1389-1396
2. Liberman UA, Weiss SR, Broll J, Minne HW, Qian H, Bell NH, Rodriguez-Portales J, Downs RW, Dequeker J, Favus M, Seeman E, Recker RR, Capizzi T, Santora AC, Lambardi A, Shah RV, Hirsch LJ, Karpf DB 1995 Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 333:1437-1443
3. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux A-C, Shah AS, Huster WJ, Draper M, Christiansen C 1997 Effect of raloxifene on bone mineral density, serum cholesterol concentrations and uterine endometrium in postmenopausal women. N Engl J Med 337:1641-1647
4. Chestnut C, Baylink DJ, Doyle D, Genant H, Harris S, Kiel D, LeBoff M, Stock JL, Gimona A, Andriano K, Richardson P 1998 Salmon calcitonin nasal spray prevents vertebral fractures in established osteoporosis. Further interim results of the PROOF study. Osteoporos Int 8(suppl 3):13
5. Fogelman I, Ribot C, Smith R, Ethgen D, Sod E, Reginster J-Y for the BMD-MN Study Group 2000 Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, controlled clinical trial. J Clin Endocrinol Metab 85:1895-1900
6. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Wasnich RD, Greenwald M, Kaufman JM, Chestnut CH, Reginster, JY 2001 Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 344:333-340
7. Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Treschel U, Widmer A, Devogelaer J-P, Kaufman J-M, Jaeger P, Body J-J, Meunier PJ 2002 Intravenous zolendronic acid in postmenopausal women with low bone mineral density. N Engl J Med 346:653-661
8. Rosen CJ, Bilezikian JP 2001 Anabolic therapy for osteoporosis. J Clin Endocrinol Metab 86:957-964
9. Dempster DW, Cosman F, Parisien M, Shen V, Lindsay R 1993 Anabolic actions of parathyroid hormone on bone. Endocr Rev 14:690-709
10. Finkelstein JS, Klibanski A, Schaefer EH, Hornstein MK, Schiff I, Neer RM 1994 Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency. N Engl J Med 331:1618-1623
11. Lindsay R, Nieves J, Formica C, Hennerman E, Woelfert L, Shen V, Dempster D, Cosman F 1997 Randomised clinical trial of the effect of parathyroid hormone on vertebral bone mass and fracture incidence among postmenopausal women with osteoporosis. Lancet 350:550-555
12. Cosman F, Nieves J, Woelfert L, Gordon S, Shen V, Lindsay R 2001 Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Metab 16:925-931
13. Hodsman AB, Fraher LJ, Watson PH, Ostbye T, Stitt LW, Adachi JD, Taves DH, Drost D 1997 A randomized controlled clinical trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 82:620-628
14. Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD 1998 Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. J Clin Invest 102:1627-1633
15. Roe EB, Sanchez SD, del Puerto GA, Pierini E, Bachetti P, Cann CE, Arnaud CD, Treatment of postmenopausal osteoporosis with human parathyroid hormone 1-34 and estrogen. Program of the 81st Annual Meeting of The Endocrine Society, San Diego, CA, 1999, p 59 (Abstract S63-1)
16. Kurland ES, Cosman F, McMahon DJ, Rosen CJ, Lindsay R, Bilezikian JP 2000 Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab 85:3069-3076
17. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster J-Y, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH 2001 Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434-1441
18. Dempster DW, Cosman F, Kurland E, Zhou H, Nieves J, Woelfert L, Shane E, Plavetic K, Muller R, Bilezikian JP, Lindsay RL 2001 Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res 16:1846-1853
19. Rittmaster RS, Bolognese M, Ettinger MP, Hanley DA, Hodsman AB, Kendler DL, Rosen CJ 2000 Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab 85:2129-2134
20. Cosman F, Nieves J, Woelfert L, Shen V, Lindsay R 1998 Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women. J Bone Miner Res 13:1051-1055
21. Stewart AF, Horst R, Deftos LJ, Cadman EC, Lang R, Broadus AE 1980 Biochemical evaluation of patients with cancer-associated hypercalcemia: evidence for humoral and non-humoral groups. N Engl J Med 303:1377-1383
22. Stewart AF, Vignery A, Silvergate A, Ravin ND, LiVolsi V, Broadus AE, Baron R 1982 Quantitative bone histomorphometry in humoral hypercalcemia of malignancy: uncoupling of bone cell activity. J Clin Endocrinol Metab 55:219-227
23. Nakayama K, Fukumoto S, Takeda S, Takeuchi Y, Ishikawa T, Miura M, Hata K, Hane M, Tamura Y, Tanaka Y, Kitaoka M, Obara T, Ogata E, Matsumoto T 1996 Differences in bone and vitamin D metabolism between primary hyperparathyroidism and malignancy-associated hypercalcemia. J Clin Endocrinol Metab 81:607-611
24. Strewler GJ 2000 The physiology of parathyroid hormone-related protein. N Engl J Med 342:177-185
25. Orloff JJ, Wu T, Heath HW, Brady T, Brines ML, Stewart AF 1989 Characterization of canine renal receptors for the parathyroid hormone-like protein associated with humoral hypercalcemia of malignancy. J Biol Chem 264:6097-6103
26. Juppner H, Abou-Samra A-B, Uneno S, Gu W-X, Potts JT, Segre GV 1988 The parathyroid hormone-like peptide associated with humoral hypercalcemia of malignancy and parathyroid hormone bind to the same receptor on the plasma membrane of ROS 17/2.8 cells. J Biol Chem 263:8557-8560
27. Segre GV 1996 Receptors for parathyroid hormone and parathyroid hormone-related protein. In: Bilezikian JP, Raisz LG, Rodan GA, eds. Principles of bone biology. San Diego: Academic Press; 377-404
28. Everhart-Caye M, Inzucchi SE, Guinness-Henry J, Mitnick MA, Stewart AF 1996 Parathyroid hormone-related protein(1-36) is equipotent with parathyroid hormone(1-34) in humans. J Clin Endocrinol Metab 81:199-208
29. Stewart AF, Cain RL, Burr DB, Turner CH, Hock JM 2000 Six month daily administration of PTH and PTHrP peptides to adult ovariectomized rats markedly enhances bone mass and biomechanics: a comparison of human PTH(1-34), PTHrP(1-36) and SDZ-PTH-893. J Bone Miner Res 15:1517-1525
30. Karaplis AC, Luz A, Glowacki J, Bronson RT, Tybulewicz VLJ, Kronenberg HM, Mulligan RC 1994 Lethal skeletal dysplasia from targeted disruption of the parathyroid hormone-related peptide gene. Genes Dev 8:277-289
31. Horwitz MJ, Tedesco MB, Sereika SM, Garcia-Ocana A, Stewart AF, Parathyroid hormone-related protein is equipotent to parathyroid hormone in both hypercalcemic and anticalciuric actions: implications for humoral hypercalcemia of malignancy. Program of the 84th Annual Meeting of The Endocrine Society, San Francisco, CA, 2002, p 93 (Abstract OR21-4)
32. Henry JG, Mitnick MA, Dann PR, Stewart AF 1997 Parathyroid hormone-related protein (1-36) is biologically active when administered subcutaneously to humans. J Clin Endocrinol Metab 82:900-906
33. Papapoulos SE, Manning RM, Hendy GN, Lewin IG, O'Riordan JLH 1990 Studies of circulating parathyroid hormone in man using a homologous amino-terminal specific immunoradiometric assay. Clin Endocrinol 13:57-67
34. Kent GN, Loveridge N, Reeve J, Zanelli JM 1985 Pharmacokinetics of synthetic human parathyroid hormone 1-34 in man measured by cytochemical bioassay and radioimmunoassay. Clin Sci 68:171-177
35. Stewart A, Mangin M, Wu T, Goumas D, Insogna KL, Burtis WJ, Broadus AE 1988 A synthetic human parathyroid hormone-like protein stimulates bone resorption and causes hypercalcemia in rats. J Clin Invest 81:596-600
36. Plotkin H, Gundberg C, Mitnick M, Stewart AF 1998 Dissociation of bone formation from resorption during two-week treatment with hPTHrP(1-36) in humans: potential as an anabolic therapy for osteoporosis. J Clin Endocrinol Metab 83:2786-2791
37. Gundberg CM, Nieman SD, Abrams S, Rosen H 1998 Vitamin K status and bone health: an analysis of methods for the determination of "undercarboxylated" osteocalcin. J Clin Endocrinol Metab 83:3258-3266
38. Syed MA, Horwitz MJ, Tedesco MB, Garcia-Ocaña A, Wisniewski SR, Stewart AF 2001 Parathyroid hormone-related protein (1-36) stimulates renal tubular calcium reabsorption in normal human volunteers: implications for the pathogenesis of humoral hypercalcemia of malignancy. J Clin Endocrinol Metab 86:1525-1531.
39. Lindsay R, Nieves J, Henneman E, Shen V, Cosman F 1993 Subcutaneous administration of the amino-terminal fragment of human parathyroid hormone-(1-34): kinetics and biochemical response in estrogenized osteoporotic patients. J Clin Endocrinol Metab 77:1535-1539
40. Hodsman AB, Hanley DA, Watson PH, Fraher LJ 2002 Parathyroid hormone. In: Bilezikian JP, Raisz LR, Rodau GA, eds. Principles of bone biology, ed 2. San Diego: Academic Press; 1305-1324
41. Dobnig H, Turner RH 1997 Effects of programmed administration of human parathyroid hormone fragment (1-34) on bone histomorphometry and serum chemistry in rats. Endocrinology 138:4607-4612